Sumatriptan Succinate
Product Images NDC 66116-413
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 66116-413). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1: Estimated Probability Of Achieving Initial Headache Response Within 240 Minutes* (2fbc01fb B787 4ff1 Bb9f 280dfe975531 02)
Figure 2: The Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment* (2fbc01fb B787 4ff1 Bb9f 280dfe975531 03)
The text seems to depict a chart or graph displaying the effects of different dosages (placebo, 25mg, 50mg, and 100mg) over time (up to 20 hours) in response to a certain medication or treatment. However, without more context it is difficult to provide a more specific description of the data being presented.*
Sumatriptan Succinate Tablets 50mg (2fbc01fb B787 4ff1 Bb9f 280dfe975531 04)
This text contains information related to a Sumatriptan medication provided by medvantx.com, including dosage instructions and a phone number to call in case the medication runs out. There's also an expiration date and lot number provided, as well as a warning to keep the container tightly closed and out of reach of children. The text appears to be a sample from Teva Pharmaceuticals USA and is not available for sale.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.